U0126, a specific MEK1/2 inhibitor but low potency drug [38,39], was used with encouraging results in the treatment of an FGFR2-induced craniosynostosis mouse model [7], and we have shown that it can effectively regulate Erf localization and function [14]. The gene discussed is ERF; the disease is craniosynostosis.